Has Fatima Rodriguez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $138,745 in general payments to Fatima Rodriguez, MD across 114 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fatima Rodriguez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fatima Rodriguez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fatima Rodriguez, MD

Cardiovascular Disease · Stanford, CANPI 1184918393

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $126,408 of the $138,745 with a category attached, or 91.1%. 12 manufacturers reported payments, led by Novartis at 33.0% of the total. 2025 is the largest year on record at $71,982, more than ten times the $57 reported in 2019. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$138,745in general payments, 2019–2025

Across 114 payments — averaging $1217.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$46K
Heartflow, Inc.$38K
Edwards Lifesciences$15K
Janssen Global Services, LLC$15K
Amgen$10K
Esperion Therapeutics, Inc.$8K
plus $7K from 6 others

$319,830in research payments, 2019–2025

Across 179 payments — averaging $1786.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$267K
Novartis$26K
Cleerly, Inc.$23K
Regeneron$2K
Amgen$2K

What the payments were for

Consulting fees$126,40891%
Speaking & faculty fees$4,0003%
Travel & lodging$3,6533%
Food & beverage$4,6843%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	42	$45,747
Heartflow, Inc.	19	$38,440
Edwards Lifesciences	12	$15,240
Janssen Global Services, LLC	11	$14,557
Amgen	11	$9,781
Esperion Therapeutics, Inc.	7	$8,257
E.r. Squibb & Sons, L.L.C.	1	$3,600
Irhythm Technologies, Inc.	2	$2,518
Cleerly, Inc.	3	$343
Janssen Scientific Affairs, LLC	3	$169
Novo Nordisk	2	$63
Johnson & Johnson	1	$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FFRct$38,409
LEQVIO$29,101
Edwards SAPIEN 3 Transcatheter Heart Valve$14,219
NEXLIZET$8,000
NEXLETOL$8,000
Zio monitor$2,518
ZIO XT Patch$2,518
SAPIEN 3 Ultra RESILIA$580
Cleerly Ischemia$272
Cleerly Labs$272
XARELTO$112
ENTRESTO$103

How this compares

$138,745 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$35,382

Medicare patients

738

Services billed

917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VascepaIcosapent Ethyl	12	$4,285
Dabigatran EtexilateDabigatran Etexilate Mesylate	12	$2,015
Rosuvastatin Calcium	54	$964
Ezetimibe	30	$891
Metoprolol Succinate	48	$641
Losartan Potassium	55	$445
Amlodipine Besylate	40	$299
ClopidogrelClopidogrel Bisulfate	14	$293
Atorvastatin Calcium	30	$285

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Stanford

Wilber SuStanford$1.1M
Euan AshleyStanford$508K
Kenneth MahaffeyStanford$447K
Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M
Matthew BudoffTorrance$3.6M
Eric Topolla Jolla$2.2M
Cathleen Bairey-MerzLos Angeles$1.2M
Gagan SinghSacramento$1.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →